

# Transcranial Magnetic Stimulation (for Ohio Only)

Policy Number: CS124OH.I – P  
Effective Date: February 1, 2023

[➔ Instructions for Use](#)

Table of Contents	Page
<a href="#">Application</a> .....	1
<a href="#">Coverage Rationale</a> .....	1
<a href="#">Applicable Codes</a> .....	1
<a href="#">Description of Services</a> .....	2
<a href="#">Clinical Evidence</a> .....	2
<a href="#">U.S. Food and Drug Administration</a> .....	11
<a href="#">References</a> .....	11
<a href="#">Policy History/Revision Information</a> .....	13
<a href="#">Instructions for Use</a> .....	14

Related Policies
<ul style="list-style-type: none"> <li>• <a href="#">Deep Brain and Cortical Stimulation (for Ohio Only)</a></li> <li>• <a href="#">Vagus and External Trigeminal Nerve Stimulation (for Ohio Only)</a></li> </ul>

## Application

This Medical Policy only applies to the state of Ohio.

## Coverage Rationale

The following are unproven and not medically necessary due to insufficient evidence of efficacy:

- Transcranial magnetic stimulation for treating all medical (i.e., non-behavioral) conditions including but not limited to:
  - Alzheimer’s disease
  - Chronic neuropathic pain
  - Dystonia
  - Epilepsy
  - Headaches
  - Parkinson’s disease
  - Stroke
  - Tinnitus
- Navigated transcranial magnetic stimulation (nTMS) for treatment planning or for diagnosing motor neuron diseases or neurological disorders

For Behavioral Disorders, refer to the Optum Behavioral Clinical Policy titled [Transcranial Magnetic Stimulation](#) at Optum Provider Express > Clinical Resources > Guidelines/Policies & Manuals > [Behavioral Clinical Policies](#).

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
64999	Unlisted procedure, nervous system
90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management
90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session
90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management

*CPT® is a registered trademark of the American Medical Association*

## Description of Services

Transcranial magnetic stimulation (TMS) is a method of delivering electrical stimulation to the brain. In general, single-pulse TMS is used to explore brain functioning and repetitive TMS (rTMS) is used to induce changes in brain activity that lasts beyond the stimulation period (Klomjai et al. 2015). Single-pulse TMS was originally introduced in 1985 as a noninvasive and safe way to stimulate the cerebral cortex. Activation of the motor cortex by transcranial magnetic stimulation produces contralateral muscular-evoked potentials (MEPs), thus providing a valuable tool for functional mapping of the motor cortex. Technological advances introduced generators capable of producing rapid, repetitive pulses of magnetic stimulation. The magnetic field pulses pass unimpeded through the hair, skin, and skull and into the brain where they induce an electrical current to flow inside the brain without seizures or need for anesthesia. The amount of electricity created is very small and cannot be felt by the individual, but the electric charges cause the neurons to become active and are thought to lead to the release of neurotransmitters such as serotonin, norepinephrine and dopamine. Repetitive TMS (rTMS) is currently under investigation as a treatment for several disorders originating in the cerebral cortex including pain, dystonia, epilepsy, headaches, Parkinson's disease, stroke, and tinnitus. TMS is delivered by various available devices, and treatment has been tested using a variety of protocols, including high frequency delivered over the left dorsolateral prefrontal cortex, low frequency delivered over the right or left dorsolateral prefrontal cortex, bi-lateral delivery, deep TMS in which deeper prefrontal regions are stimulated and theta burst stimulation that delivers magnetic pulses that are administered at a rapid speed of delivery.

Navigated transcranial magnetic stimulation (nTMS) is being studied as a diagnostic tool to stimulate functional cortical areas at precise anatomical locations to induce measurable responses. This technology is being investigated to map functionally essential motor areas for diagnostic purposes and for treatment planning.

## Clinical Evidence

### Therapeutic Transcranial Magnetic Stimulation (TMS)

The current evidence is insufficient to determine the efficacy of TMS for treating conditions such as Alzheimer's disease, epilepsy, headaches, pain, Parkinson's disease, stroke, and tinnitus. Due to small sample sizes, short-term follow-ups, and variability in technique and outcome measures, there is insufficient data to conclude that transcranial magnetic stimulation is beneficial for treating these conditions.

### *Alzheimer's Disease (AD)*

Holczer et al. (2020) conducted a systematic review to examine the presence and extent of methodological issues confounding non-invasive brain stimulation (NIBS) studies attempting to alleviate the cognitive symptoms of demented patients. However, serious methodological limitations appear to affect the estimates of their efficacy. The focus was on repetitive transcranial magnetic stimulation (rTMS) or tDCS, i.e., the two most frequent NIBS techniques. Patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) were included. The study reviewed the stimulation parameters and methods of studies that used TMS or tDCS to alleviate the cognitive symptoms of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI). The risk of bias was also included in these studies. There were 36 studies identified of which 23 were randomized-controlled trials. More than 75% of randomized-controlled trials involved some levels of bias in at least one domain. Stimulation parameters were highly variable with some ranges of effectiveness emerging. Studies with low risk of bias indicated TMS to be potentially effective for patients with AD or MCI while questioned the efficacy of tDCS. This was the first time the presence and extent of methodical issues affecting TMS and tDCS research involving patients with AD and MCI were examined. The risk of

bias frequently affected the domains of the randomization process and selection of the reported data while missing outcome was rare. Unclear reporting was present involving randomization, allocation concealment, and blinding. Methodological awareness can potentially reduce the high variability of the estimates regarding the effectiveness of TMS and tDCS. Studies with low risk of bias delineate a range within TMS parameters seem to be effective but question the efficacy of tDCS. The study also had limitations including the lack of quality assessment of the non-RCTs as well as a quantitative analysis. Only the measurements of cognitive domain were considered and most neuropsychiatric symptoms are considered to be closely linked with cognitive disturbances causing reduced quality of life in neurodegenerative disorders. Author's note that based on the currently literature, it is difficult to conclude the effectiveness of NIBS methods in dementia research.

Lin et al. (2019) conducted a systematic review and meta-analysis to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) on cognitive function in patients with AD. A total of 12 studies with 231 patients were included, with 8 randomized controlled studies and 4 self-controlled studies. Eleven studies used high frequency rTMS ( $\geq 5$  Hz), but only one study directly compared the difference between low-frequency (1 Hz) and high-frequency (20 Hz). Random-effects analysis showed that rTMS could significantly improve cognition compared with sham-rTMS (SMD: 0.60, 95% CI: 0.35-0.85,  $P < .0001$ ). In subgroup analyses, the effect for stimulation at a single target was 0.13 (95% CI: -0.35-0.62) and multiple targets 0.86 (95% CI: 0.18-1.54). Treatment for  $\leq 3$  sessions produced an effect of 0.29 (95% CI: -1.04-1.62), whereas treatment for  $\geq 5$  sessions produced an effect of 2.77 (95% CI: 2.22-3.32). No differences were found for rTMS combined with medication or cognitive training. The authors concluded that rTMS can significantly improve cognitive ability in patients with mild to moderate AD. According to the authors, several limitations of this meta-analysis should be considered. First, the number of studies and sample size in the meta-analysis were small. Second, although the efficacy of rTMS was evaluated, there was no assessment of the effect of duration due to inadequate data. Third, the presence of heterogeneity between studies was inevitable and this inconsistency may have influenced the results. Further trials with larger samples are needed to explore the optimal parameters and verify the effect of rTMS on cognition in AD patients.

Hayes (2019) published a report on neuroAD Therapy System for Alzheimer disease. Hayes concluded that there is not enough evidence to draw firm conclusions regarding the efficacy of the neuroAD device in patients with mild to moderate AD.

Dong et al. (2018) conducted a systematic review and meta-analysis to evaluate the efficacy and safety of rTMS in AD. Five randomized controlled trials (RCTs) involving 148 participants were included in this review. Compared with sham stimulation, high-frequency rTMS led to a significant improvement in cognition as measured by Assessment Scale-cognitive subscale (ADAS-cog), but not (Mini-Mental State Examination) MMSE. High-frequency rTMS also improved the global impression in comparison to the placebo. There was no significant difference in mood and functional performance between high-frequency rTMS and sham groups. Only one trial included low-frequency rTMS reported no significant improvement in cognition, mood and functional performance. Few mild adverse events were observed in both the rTMS and sham groups. The authors concluded that rTMS is relatively well tolerated, with some promise for cognitive improvement and global impression in patients with AD. According to the authors, a limitation of this meta-analysis is that the sample size was too small to ensure adequate power to detect a significant difference in primary outcomes among groups.

According to the National Institute for Health and Care Excellence (NICE) guideline for dementia: assessment, management and support for people living with dementia and their carers (2018), non-invasive brain stimulation (including transcranial magnetic stimulation) should not be offered to treat mild to moderate Alzheimer's disease, except as part of a randomized controlled trial.

## ***Epilepsy***

In a Cochrane review, Chen et al. (2016) assessed the evidence for the use of TMS in individuals with drug-resistant epilepsy compared with other available treatments in reducing seizure frequency and improving quality of life. Seven randomized controlled trials that were double-blinded, single-blinded or unblinded, and placebo, no treatment, or active controlled were included in the analysis. The total number of participants in the seven trials was 230. Two of the seven studies analyzed showed a statistically significant reduction in seizure rate from baseline (72% and 78.9% reduction of seizures per week from the baseline rate, respectively). The other five studies showed no statistically significant difference in seizure frequency following rTMS treatment compared with controls. The authors judged the quality of evidence for the primary outcomes of this review to be low. According to the authors, there is evidence that rTMS is safe and not associated with any adverse events but given the variability in technique and outcome reporting that prevented meta-analysis, the evidence for efficacy of rTMS for seizure reduction is still lacking despite reasonable evidence that it is effective at reducing epileptiform discharges.

## Headaches

Moisset et al. (2020) conducted a systematic review with meta-analysis of RCTs focusing on neurostimulation techniques for migraine treatment. Several non-invasive and even invasive neurostimulation methods have been proposed for acute or preventive migraine treatment. The target population was patients of any age, including children, with migraine according to the international classification of headache disorders (ICHD) criteria. The migraine conditions considered included both episodic and chronic migraine, either with or without aura. Studies focusing on other headache types, especially tension-type headaches or cluster headaches, were excluded. Outcomes for the quantitative synthesis were 2 hours pain free for acute treatment and headache days per month for preventive treatment. Subgroup analyses was done by treatment (stimulation method and site of application). Estimates were pooled using random-effects meta-analysis. Thirty-eight articles were included in the qualitative analysis (7 acute, 31 preventive) and 34 in the quantitative evaluation (6 acute, 28 preventive). Remote electrical neuromodulation (REN) was effective for acute treatment. Data were insufficient to draw conclusions for any other techniques (single studies). Invasive occipital nerve stimulation (ONS) was effective for migraine prevention, with a large effect size but considerable heterogeneity, whereas supra-orbital transcutaneous electrical nerve stimulation (TENS), percutaneous electrical nerve stimulation (PENS), and high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex (M1) were effective, with Vagus-nerve stimulation, left prefrontal cortex rTMS, and cathodal transcranial direct current stimulation (tDCS) over the M1 had no significant effect and heterogeneity was high. Six studies tested repetitive TMS. There are several neuromodulation methods that are of potential interest for migraine management, but the quality of the evidence is very poor. This review had several limitations. The meta-analysis was based on a very limited number of articles for each study sub-group and the estimation of effect size may not be accurately driven. The methodological quality of the studies was heterogenous. The follow-up period was very short, and long-term benefits of neuromodulation are yet to be proven. Future large and well-conducted studies are needed and could improve on the present results.

Stilling et al. (2019) performed a systematic review on the use of TMS and transcranial direct current stimulation (tDCS) for the treatment of specific headache disorders (i.e., migraine, tension, cluster, posttraumatic). Studies were selected by inclusion criteria for participants (adults 18-65 with primary or secondary headaches), interventions (TMS and tDCS applied as headache treatment), comparators (sham or alternative standard of care), and study type (cohort, case-control, and randomized controlled trials [RCT]). Thirty-four studies were included: 16 rTMS, 6 TMS (excluding rTMS), and 12 tDCS. The majority investigated treatment for migraine (19/22 TMS, 8/12 tDCS). The quality of the studies ranged from very low to high. The authors concluded that rTMS is the most promising with moderate evidence that it contributes to reductions in headache frequency, duration, intensity, abortive medication use, depression, and functional impairment. However, only a few studies reported changes greater than sham treatment. Further high-quality RCTs with standardized protocols are required for each specific headache disorder to validate a treatment effect.

Reuter et al. (2019) performed a systematic review of 71 clinical trials to inform clinical decisions about non-invasive neuromodulation for migraine and cluster headaches. Non-invasive vagus nerve stimulation (nVNS), single-transcranial magnetic stimulation (sTMS) and external trigeminal nerve stimulation (all with regulatory clearance) were well studied compared with the other devices, for which studies frequently lacked proper blinding, sham controls and sufficient population sizes. sTMS which includes the Cerena Transcranial Magnetic Stimulator (eNeural Therapeutics) and the SpringTMS device (eNeural Therapeutics) was evaluated in three published studies for the acute and preventive treatment of migraine. According to the authors, nVNS studies demonstrated the most consistent adherence to available guidelines. According to the authors, the scope of this systematic review was limited by the heterogeneity among the clinical trials analysed and the unavailability of many of the study results, which precluded a formal systematic meta-analysis of all identified studies.

In a systematic review of controlled clinical trials, Shirahige et al. (2016) evaluated the efficacy of noninvasive brain stimulation (NIBS) on pain control in migraine patients. Eight studies were included in the quantitative analysis with 153 migraine patients who received NIBS and 143 patients who received sham NIBS. In the overall meta-analysis, the authors did not find significant results for pain intensity, for migraine attacks, and for painkiller intake. However, subgroup analysis considering only transcranial direct current stimulation (tDCS) effects demonstrated a decrease for pain intensity, migraine attacks, and painkiller intake. Subgroup analysis for TMS did not reveal significant effects for any outcome. The authors concluded that this review failed to find support for the superiority of NIBS over sham treatment. According to the authors, there is a need for larger controlled trials with methodological rigor, which could increase the power of result inference.

According to the National Institute for Health and Care Excellence (NICE) Guideline for transcranial magnetic stimulation for treating and preventing migraine (2014), evidence on the efficacy of TMS for the treatment of migraine is limited in quantity and for the prevention of migraine is limited in both quality and quantity. Evidence on its safety in the short and medium term is

adequate but there is uncertainty about the safety of long-term or frequent use of TMS. Therefore, according to NICE, this procedure should only be used with special arrangements for clinical governance, consent and audit or research.

## ***Clinical Practice Guidelines***

### **European Headache Federation**

In a position statement for neuromodulation of chronic headaches, the European Headache Federation states that application of the noninvasive rTMS in chronic headaches is not yet evidence based, given the poor amount of controlled data (Martelletti et al. 2013).

### **Parkinson's Disease (PD)**

Xie et al. (2020) systematically assessed the effectiveness of rTMS intervention on gait in individuals with PD. The inclusion criteria for this review were RCTs, exploring the effect of rTMS in patients diagnosed with idiopathic PD. Among 14 eligible studies, including 298 participants were analyzed in this meta-analysis. Walking time was improved with rTMS compared with sham rTMS (standardized mean difference [SMD] -0.30; 95% confidence interval [CI], -0.57 to -0.03;  $P=.03$ ). The score for the freezing of gait questionnaire did not differ significantly between rTMS and no intervention. Four studies compared Timed Up and Go (TUG) test between the 2 treatment groups and no significant differences were found between the rTMS and control group (SMD -0.45; 95% CI, -1.32 to 0.41;  $P=.30$ ). During the off-state, there were no significant differences in estimated effect sizes (SMD=-0.29; 95% CI, -0.79 to 0.21;  $P=.25$ ), which is significantly different in on-state (SMD -0.98; 95% CI, -1.78 to -0.18;  $P=.02$ ) evaluation. The authors concluded that the results of the meta-analysis propose the favorable effect of rTMS on walking performance in the short term but not over the long term. The limitations of this meta-analysis may be that the unclear risk of bias on certain domains constrained the results due to incomplete data in a few studies. In addition, the sample size of the included studies was relatively small. Larger RCTs with improved study methodology are needed to evaluate the effectiveness of rTMS for patients with PD.

Yang et al. (2018) performed a meta-analysis to evaluate the optimal rTMS parameters for motor recovery of PD. Electronic databases were searched for studies investigating the therapeutic effects of rTMS on motor function in patients with PD. Twenty-three studies with a total of 646 participants were included. The pooled estimates of rTMS revealed significant short-term and long-term effects on motor function improvement of PD. Subgroup analysis observed that high-frequency rTMS (HF-rTMS) was significant in improving motor function, but low-frequency rTMS (LF-rTMS) was not. In particular, when HF-rTMS targeted over the primary motor cortex (M1), in which the bilateral M1 revealed a larger effect size than unilateral M1. Compared to single-session, multi-session of HF-rTMS over the M1 showed significant effect size. In addition, HF-rTMS over the M1 with a total of 18,000-20,000 stimulation pulses yielded more significant effects than other dosages. According to the authors, these results suggest that rTMS might be helpful in improving the motor deficits of PD patients. The authors stated that there are limitations of this meta-analysis. First, the experimental designs of the included studies were not homogenous (e.g., randomized controlled trials versus crossover design). Second, the selected participants varied in age, disease stage, and other biological characteristics that may have confounded the results.

Goodwill et al. (2017) conducted a meta-analysis that quantified the effectiveness of rTMS to improve motor and cognitive dysfunction in PD. A total of 24 rTMS with a sham control group were included in the analyses. The results showed an overall positive effect in favor of rTMS compared with sham stimulation on motor function. The use of rTMS did not improve cognition. No effects for stimulation parameters on motor or cognitive function were observed. The authors acknowledged several limitations. Studies evaluating rTMS demonstrated modest effect sizes (0.4–0.6) and large heterogeneity between studies. Clinical and lifestyle variables including PD-related comorbidity, physical activity levels and other mental health conditions were not accounted for in the subgroup analyses, which may have influenced the responsiveness to non-invasive brain stimulation (NBS).

In a systematic review and meta-analysis, Wagle Shukla et al. (2016) reviewed the literature on clinical repetitive rTMS trials in Parkinson's disease to quantify the overall efficacy of this treatment. Prospective clinical trials were included that had an active arm and a control arm and change in motor scores on Unified Parkinson's Disease Rating Scale as the primary outcome. The authors pooled data from 21 studies that met these criteria and analyzed separately the effects of low- and high-frequency rTMS on clinical motor improvements. Repetitive transcranial magnetic stimulation therapy demonstrated benefits at short-term follow-up (immediately after a treatment protocol) with a pooled mean difference of 3.4 points as well as at long-term follow-up (average follow-up 6 weeks) with mean difference of 4.1 points. The authors concluded that rTMS therapy results in mild-to-moderate motor improvements and has the potential to be used as an adjunct therapy for the treatment of Parkinson's disease.

According to the authors, future large, sample studies should be designed to isolate the specific clinical features of Parkinson's disease that respond well to rTMS therapy. The authors indicated that the literature on the use of rTMS for levodopa-induced dyskinesia, objective bradykinesia, and gait measures is sparse and that on the basis of the current available information, the results are conflicting, and no clear treatment protocol has yet been defined.

## **Pain**

Yu et al. (2020) conducted a meta-analysis examining the effectiveness of the effects of overall noninvasive brain stimulation (NIBS) on post-spinal cord injury (SCI) neuropathic pain (NP). A meta-analysis on pain intensity, depression, and anxiety levels was conducted to evaluate the effect of noninvasive brain stimulation on neuropathic pain in individuals with spinal cord injury.

Eleven studies were selected including eight RCT's and three cross-over RCTs. All studies compared an active NIBS group with a sham group. The intervention of these studies included rTMS (four trials), tDCS (six trials), and CES (one trial). The pooled analysis demonstrated no significant effect of repetitive transcranial magnetic stimulation, transcranial direct current stimulation, or cranial electrotherapy stimulation on neuropathic pain reduction after spinal cord injury. In addition, noninvasive brain stimulation showed no beneficial effect over sham stimulation on the improvement of depression, while it yielded a significant reduction of anxiety levels immediately after treatment. Subgroup analysis showed that only cranial electrotherapy stimulation had a significant effect on the reduction of anxiety levels among the three types of noninvasive brain stimulation. There are limitations with the study including the small number evaluated for each type of stimulation, most subjects were male and only studies that contained pain were included whereas those only examined anxiety and depression may have been missed. The overall findings indicated that noninvasive brain stimulation had no significant effect on pain reduction in individuals with post-SCI NP, but cranial electrotherapy stimulation might be useful in the management of anxiety in these individuals. These findings do not support the routine use of noninvasive brain stimulation for NP in individuals with SCI. Further studies are needed with larger sample size to support this technology.

Gatzinsky et al. (2020) conducted a systematic review to evaluate the effects of high frequency rTMS of M1 in the treatment of chronic neuropathic pain (NP) based on the magnitude of relative pain reduction (active vs sham stimulation) and to investigate the applicability the accuracy to predict a positive response to epidural motor cortex stimulation (MCS) which is supposed to give a more longstanding pain relief. There were 32 articles included twenty-four RCTs and eight case series. Data on 5-20 Hz (high-frequency) rTMS vs. sham was extracted from 24 blinded randomised controlled trials which varied in quality, investigated highly heterogeneous pain conditions, and used extremely variable stimulation parameters. The difference in pain relief between active and sham stimulation was statistically significant in 9 of 11 studies using single-session rTMS, and in 9 of 13 studies using multiple sessions. Baseline data could be pulled out from 6 single and 12 multiple session trials with a weighted mean pain reduction induced by active rTMS, compared to baseline, of -19% for single sessions, -32% for multiple sessions with follow-up <30 days, and -24% for multiple sessions with follow-up ≥30 days after the last stimulation session. For single sessions the weighted mean difference in pain reduction between active rTMS and sham was 15 percentage points, for multiple sessions the difference was 22 percentage points for follow-ups <30 days, and 15 percentage points for follow-ups ≥30 days. Four studies reported data that could be used to evaluate the precision of rTMS to predict response to MCS, showing a specificity of 60-100%, and a positive predictive value of 75-100%. There were no serious adverse events reported. rTMS targeting M1 can result in significant reduction of chronic NP which, however, is transient and shows a great heterogeneity between studies; very low certainty of evidence for single sessions and low for multiple sessions. Multiple sessions of rTMS can sustain a longer effect. rTMS seems to be a fairly good predictor of a positive response to epidural MCS and may be used to select patients for implantation of permanent epidural electrodes. Additional studies on the efficacy of rTMS for different types of NP is needed. Major knowledge gaps remain concerning the long-term effects of rTMS on HRQoL and the use of analgesic medication. These vital conclusion variables need to be addressed more consistently in future studies to validate the routine use of rTMS in chronic pain management.

Hamid et al. (2019) systematically reviewed and evaluated the current literature on TMS for patients suffering from chronic pain, assessed its efficacy, and estimated the best stimulation protocol. Twelve RCTs were included involving 350 patients with focal and generalized chronic pain. An existing proof showed a null response of low-frequency rTMS stimulation, rTMS delivered to the dorsolateral prefrontal cortex in chronic pain patients. However, a witnessed pain-killing response was documented when applying active high-frequency TMS on the motor cortex M1 area compared to sham. Pain relief was detected for a short time following the application of active high-frequency motor cortex stimulation in nine clinical trials, and the long-lasting analgesic effect was proved. No side effects were mentioned for the technique. The authors concluded that although TMS is a safe, promising technique to reduce long-lasting refractory pain, the evidence is hampered and influenced by multifactorial stimulation parameters. Additional research efforts are needed to highlight the best optimal stimulation protocol and to

standardize all parameters to promote the long-term efficacy of rTMS as a noninvasive alternative in the management of chronic refractory pain.

Galhardoni et al. (2019) compared the analgesic effects of stimulation of the anterior cingulate cortex (ACC) or the posterior superior insula (PSI) against sham deep (d) rTMS in patients with central neuropathic pain (CNP) after stroke or spinal cord injury in a randomized, double-blinded, sham-controlled, 3-arm parallel study. Participants were randomly allocated into the active PSI-rTMS, ACC-rTMS, sham-PSI-rTMS, or sham-ACC-rTMS arms. Stimulations were performed for 12 weeks, and a comprehensive clinical and pain assessment, psychophysics, and cortical excitability measurements were performed at baseline and during treatment. The main outcome of the study was pain intensity (numeric rating scale [NRS]) after the last stimulation session. Ninety-eight patients (age  $55.02 \pm 12.13$  years) completed the study. NRS score was not significantly different between groups at the end of the study. Active rTMS treatments had no significant effects on pain interference with daily activities, pain dimensions, neuropathic pain symptoms, mood, medication use, cortical excitability measurements, or quality of life. Heat pain threshold was significantly increased after treatment in the PSI-dTMS group from baseline (1.58, 95% confidence interval [CI] 0.09-3.06)) compared to sham-dTMS (-1.02, 95% CI -2.10 to 0.04,  $p = 0.014$ ), and ACC-dTMS caused a significant decrease in anxiety scores (-2.96, 95% CI -4.1 to -1.7]) compared to sham-dTMS (-0.78, 95% CI -1.9 to 0.3;  $p = 0.018$ ). The authors concluded that ACC- and PSI-dTMS were not different from sham-dTMS for pain relief in CNP despite a significant antinociceptive effect after insular stimulation and anxiolytic effects of ACC-dTMS.

In an updated version the Cochrane review published in 2014, O'Connell et al. (2018) evaluated the efficacy of non-invasive brain stimulation techniques in chronic pain. The update included a total of 42 rTMS studies. The meta-analysis of rTMS studies versus sham for pain intensity at short-term follow-up (0 to < 1-week postintervention), (27 studies, involving 655 participants), demonstrated a small effect with heterogeneity. This equates to a 7% reduction in pain, or a 0.40-point reduction on a 0 to 10 pain intensity scale, which does not meet the minimum clinically important difference threshold of 15% or greater. The authors concluded that there is very low-quality evidence that single doses of high-frequency rTMS of the motor cortex may have short-term effects on chronic pain and quality of life. However, multiple sources of bias exist that may have influenced the observed effects. The authors stated that they did not find evidence that low-frequency rTMS or rTMS applied to the dorsolateral prefrontal cortex are effective for reducing pain intensity in chronic pain. According to the authors, there remains a need for substantially larger, rigorously designed studies, particularly of longer courses of stimulation.

Saltychev and Laimi (2017) investigated whether there is evidence of repetitive transcranial magnetic stimulation (rTMS) being effective in decreasing the severity of pain among patients with fibromyalgia. Seven trials were included in the meta-analysis. The risk of bias was considered low for seven studies. Pain severity before and after the last stimulation decreased by -1.2 points on 0-10 numeric rating scale. Pain severity before and 1 week to 1 month after the last stimulation decreased by -0.7 points. Both pooled results were below the minimal clinically important difference of 1.5 points. The authors did not find evidence of clinically significant effectiveness of rTMS in decreasing the severity of fibromyalgia pain immediately after the treatment as well as in short-term follow-up.

Goudra et al. (2017) evaluated the role of repetitive transcranial magnetic stimulation (rTMS) in the treatment of chronic pain. Studies comparing rTMS and conventional treatment for chronic pain were searched. The comparison was made for decrease in the pain scores with and without (sham) the use of rTMS after a follow-up interval of 4-8 weeks. All reported pain scores were converted into a common scale ranging from "0" (no pain) to "10" (worst pain). Nine trials with 183 patients in each of the groups were included in the analysis. The decrease in pain scores with rTMS was 1.12 and in sham-rTMS was 0.28. The pooled mean drop in pain scores with rTMS therapy was higher by 0.79. The duration and frequency of rTMS were highly variable across trials. Publication bias was unlikely. The authors concluded that the use of rTMS improves the efficacy of conventional medical treatment in chronic pain patients. This treatment is not associated with any direct adverse effects. However, according to the authors, the duration and frequency of rTMS therapy is presently highly variable and needs standardization. According to the authors, availability of a limited number of trials examining the usefulness of rTMS is an important drawback of the current meta-analysis.

## ***Clinical Practice Guidelines***

### **European Academy of Neurology (EAN)**

Cruccu et al. (2016) conducted a systematic review and meta-analysis of trials to update previous European Federation of Neurological Societies guidelines on neurostimulation for neuropathic pain. The GRADE system was used to assess quality of evidence and propose recommendations. Weak recommendations were given for the use of primary motor cortex (M1) rTMS in

neuropathic pain and fibromyalgia and inconclusive recommendations were given regarding complex regional pain syndrome (CRPS). There were inconclusive recommendations regarding rTMS of the dorsolateral prefrontal cortex (DLPFC) in fibromyalgia and neuropathic pain.

## Stroke

Xie et al. (2021) conducted a systematic review and network meta-analysis (NMA) looking at the different modalities of transcranial magnetic stimulation (TMS) on lower extremity motor function and corticospinal excitability in patients with stroke. This systematic review and NMA of TMS for patients with stroke included data from 26 RCTs, including 943 participants who were randomized to one of four rTMS interventions (deep, high frequency, low-frequency, and intermittent theta-burst rTMS) or sham stimulation. Only LF-rTMS was superior to sham stimulation for motor function improvement, as measured by the FMA. Although direct evidence suggested that HFrTMS was more effective than sham stimulation for speed, this result was not replicated in the NMA. In addition, HFrTMS appeared to be more effective than LF-rTMS for MEP amplitudes. Network meta-analysis results of 18 randomized controlled trials regarding lower extremity motor function recovery revealed that low frequency rTMS had better efficacy in promoting lower extremity motor function recovery than sham stimulation. Network meta-analysis results of five randomized controlled trials demonstrated that high-frequency rTMS led to higher amplitudes of motor evoked potentials than low-frequency rTMS or sham stimulation. These findings suggest that rTMS can improve motor function in patients with stroke, and that low-frequency rTMS mainly affects motor function, whereas high-frequency rTMS increases the amplitudes of motor evoked potentials. This study had limitations including an unclear risk of bias on allocation. Also, some nodes were not connected which may have led to inaccurate results. Additional high-quality randomized controlled trials are needed to confirm this conclusion and support the effects of idTMS in stroke patients. This study is registered in PROSPERO (registration No. CRD42020147055).

Ghayour-Najafabadi et al. (2019) conducted a systematic review with meta-analysis to investigate the effectiveness of rTMS in recovery of lower limb dysfunction in patients poststroke. Fifteen trials with 385 patients were included. Results showed that rTMS had a significant effect on balance (standard mean difference [SMD] = .38; 95% confidence interval [CI], .07: .69; I<sup>2</sup> = 51%) and mobility (SMD: -.67; 95% CI, -1.08: -.26; I<sup>2</sup> = 72%). However, rTMS had no significant immediate effects on the lower limb subscale of the Fugl-Meyer Assessment (FMA-L) (SMD = .01; 95% CI, -.29: .31; I<sup>2</sup> = 0%). Continued effects of rTMS was also found to be significant during the follow-up period (SMD = .46; 95% CI, .09: .84; I<sup>2</sup> = 14%). According to the authors, this study suggests that rTMS may be more effective than no treatment or sham for improving lower limb motor function in the immediate post-therapy to 30 day follow-up period. Although there are large effect sizes that support a recommendation for rTMS intervention, the existing level of evidence is poor and further trials are needed to strengthen this preliminary finding.

In a systematic review, Cotoi et al. (2019) evaluated the effectiveness of theta-burst stimulation for the treatment of stroke-induced unilateral spatial neglect. Nine studies met the inclusion criteria, generating a total of 148 participants. Eight studies evaluated a continuous stimulation protocol and one study investigated an intermittent stimulation protocol. Overall, both protocols significantly improved neglect severity when compared against placebo or active controls ( $P < 0.05$ ). This systematic review found that theta-burst stimulation seems to improve post-stroke unilateral spatial neglect, but because the evidence is limited to a few small studies with varied and inconsistent protocols and use of terminology, no firm conclusion on effectiveness can be drawn.

In a systematic review, Sebastianelli et al. (2017) summarized the evidence for the effectiveness of low-frequency (LF) repetitive transcranial magnetic stimulation (rTMS) in promoting functional recovery after stroke. Sixty-seven studies were included in the review. The authors observed considerable heterogeneity across studies in the stimulation protocols. According to the authors, the use of different patient populations, regardless of lesion site and stroke etiology, different stimulation parameters and outcome measures means that the studies were not readily comparable, and estimating real effectiveness or reproducibility was very difficult. The authors concluded that LF rTMS over unaffected hemisphere may have therapeutic utility, but the evidence is still preliminary and the findings need to be confirmed in further randomized controlled trials.

Dionísio et al. (2017) conducted a systematic review to provide information regarding the application of repetitive transcranial magnetic stimulation (rTMS) in stroke patients and to assess its effectiveness in clinical rehabilitation of motor function. Seventy trials were included in the review. The majority of the articles reported rTMS showing potential in improving motor function, although some negative reports, all from randomized controlled trials, contradicted this claim. According to the authors, future studies are needed because there is a possibility that a bias for non-publication of negative results may be present.



In a meta-analysis and systematic review, McIntyre et al. (2017) evaluated the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in improving spasticity after stroke. A literature search of multiple databases was conducted for articles published in English from January 1980 to April 2015 using select keywords. Studies were included if: 1) the population included was >50% stroke patients; 2) the sample size included  $\geq 4$  subjects; 3) the intervention applied was rTMS; and 4) upper extremity spasticity was assessed pre and post intervention. Randomized controlled trials (RCTs) were assessed for methodological quality using the Physiotherapy Evidence Database (PEDro) tool. The main outcome measurement was the Modified Ashworth Scale (MAS). Ten studies met the inclusion criteria: two RCTs (PEDro scores 8-9) and eight pre-post studies. Meta-analyses of primarily uncontrolled pre-post studies found significant improvements in MAS for elbow, wrist, and finger flexors. However, a meta-analysis of the two available RCTs failed to find a significant rTMS treatment effect on MAS for the wrist. The authors concluded that there is limited available evidence to support the use of rTMS in improving spasticity post stroke. Despite the positive findings reported, better powered and appropriately controlled trials are necessary.

## ***Tinnitus***

Liang et al. (2020) conducted a systematic review and meta-analysis to examine the effects of the effects of transcranial magnetic stimulation (rTMS) to evaluate its clinical efficacy and safety. After database selection, twenty-nine randomized studies involving 1228 chronic tinnitus patients were included. Compared with sham-rTMS, rTMS exhibited significant improvements in the tinnitus handicap inventory (THI) scores at 1 week (mean difference [MD]: -7.92, 1 month (MD: -8.52), and 6 months (MD: -6.53), post intervention; there were significant mean changes in THI scores at 1 month (MD: -14.86) and 6 months (MD: -16.37) post intervention, and the tinnitus questionnaire (TQ) score at 1 week post intervention (MD: -8.54). Nonsignificant efficacy of rTMS was found regarding the THI score 2 weeks post intervention (MD: -1.51); the mean change in TQ scores 1 month post intervention (MD: -3.67); TQ scores 1 (MD: -8.97) and 6 months (MD: -7.02) post intervention; and adverse events (odds ratios [OR]: 1.12). Egger's and Begg's tests indicated no publication bias. There were several study limitations, including, there were a limited number of subjects which limits a more accurate analysis and some results were nonsignificant, the studies only analyzed the English language, which could have lost data from other languages and due to the limited number of studies, the possibility of false negatives could not be excluded. This meta-analysis established that rTMS is effective for chronic tinnitus; however, its safety needs more proof from large sample size, multi-center studies are needed for validation.

Soleimani et al. (2016) conducted a systematic literature review and meta-analysis on the effect of repetitive transcranial magnetic stimulation (rTMS) compared with sham in chronic tinnitus patients. For the meta-analysis weighted mean differences (and standard deviations) of Tinnitus Questionnaire (TQ) and Tinnitus Handicap Inventory (THI) scores were determined. Therapeutic success was defined as difference of at least 7 points in the THI score between baseline and the follow-up assessment after treatment. Results from 15 RCTs were analyzed. For THI, the data of mean difference score in two groups, 1 and 6 month after intervention, was 6.71 and 12.89, respectively. According to the authors, these data underscore the clinical effect of rTMS in the treatment of tinnitus. The authors reported that there is high variability of studies design and reported outcomes. Replication of data in multicenter trials with a large number of patients and long-term follow-up is needed before further conclusions can be drawn.

## ***Clinical Practice Guidelines***

### **American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS)**

In a clinical practice guideline for tinnitus, the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Guideline Development Panel indicated that clinicians should not recommend TMS for the treatment of patients with persistent, bothersome tinnitus (Tunkel et al., 2014).

## **Other Conditions**

### ***Clinical Practice Guidelines***

#### **American Academy of Neurology (AAN)**

The AAN published an evidence-based practice guideline on the treatment of restless legs syndrome (RLS) in adults (Winkelman et al., 2016, Reaffirmed on October 12, 2019). The guideline states that rTMS is possibly effective in the treatment of primary moderate to severe RLS (level C). This recommendation is based on one Class II study.

In 2019, the AAN published a guideline on the treatment of tics in people with Tourette syndrome and chronic tic disorders (Pringsheim et al., 2019). According to the guideline, there is insufficient evidence to determine whether people with tics

receiving the following interventions are more or less likely than those receiving an alternate intervention to have reduced tic severity:

- Continuous theta burst transcranial magnetic stimulation of the supplementary motor area vs sham transcranial magnetic stimulation, 1 Class II study; confidence in evidence downgraded due to imprecision
- rTMS of the supplementary motor area vs sham stimulation, 1 Class II study, confidence in evidence downgraded due to imprecision (adults only)
- rTMS of the left motor or prefrontal cortex vs sham stimulation, 1 Class III study

## Navigated Transcranial Magnetic Stimulation

There is limited information from the peer-reviewed published medical literature to conclude that navigated transcranial magnetic stimulation (nTMS) is effective for treatment planning or diagnostic evaluation. Randomized controlled studies with large populations are needed to evaluate how this technology can reduce clinical diagnostic uncertainty or impact treatment planning.

Raffa et al. (2019) conducted a systematic review and meta-analysis on studies that analyzed the impact of nTMS-based motor mapping on surgery of patients affected by motor-eloquent intrinsic brain tumors, in comparison with series of patients operated without using nTMS. The impact of nTMS mapping was assessed analyzing the occurrence of postoperative new permanent motor deficits, the gross total resection rate (GTR), the size of craniotomy and the length of surgery. Only eight observational studies were considered eligible and were included in the quantitative review and meta-analysis. The pooled analysis showed that nTMS motor mapping significantly reduced the risk of postoperative new permanent motor deficits (OR = 0.54,  $p = 0.001$ , data available from eight studies) and increased the GTR rate (OR = 2.32,  $p < 0.001$ , data from seven studies). Moreover, data from four studies documented the craniotomy size was reduced in the nTMS group (-6.24 cm<sup>2</sup>,  $p < 0.001$ ), whereas a trend towards a reduction, even if non-significant, was observed for the length of surgery (-10.30 min,  $p = 0.38$ ) in three studies. Collectively, currently available literature provides data in favor of the use of nTMS motor mapping: its use seems to be associated with a reduced occurrence of postoperative permanent motor deficits, an increased GTR rate, and a tailored surgical approach compared to standard surgery without using preoperative nTMS mapping. The authors indicated that nonetheless, there is a growing need of high-level evidence about the use of nTMS motor mapping in brain tumor surgery. Well-designed randomized controlled studies from multiple Institutions are needed to continue to clarify this emerging topic. (Raffa et al. (2018) and Frey et al. (2014), which were previously cited in this policy, are included in the Raffa et al. (2019) systematic review and meta-analysis.)

Hayes (2017; updated 2019) published a report on the clinical utility of navigated transcranial magnetic stimulation for presurgical planning for brain tumors. Seven comparative studies were included in the review. Histology varied in the eligible studies, with some studies including patients with only gliomas and others including a variety of tumors or lesions (i.e., glioblastoma, astrocytoma, metastases, arteriovenous malformations, cavernoma). Although the overall body of evidence suggested that nTMS may be beneficial, a definitive conclusion could not be made due to the poor quality of the evidence. Limitations of the studies included: small, heterogeneous patient populations; retrospective study design; difference in sample sizes between groups; short-term follow-ups; and limited statistical analyses. The 2019 review identified no relevant, newly published studies on nTMS.

Sollmann et al. (2018), which was not included in the above systematic review and meta-analysis, evaluated a novel multimodal setup consisting of preoperative navigated transcranial magnetic stimulation (nTMS) and nTMS-based diffusion tensor imaging fiber tracking (DTI FT) as an adjunct to awake surgery. Sixty consecutive patients suffering from highly language-eloquent left-hemispheric low- or high-grade glioma underwent preoperative nTMS language mapping and nTMS-based DTI FT, followed by awake surgery for tumor resection. Both nTMS language mapping and DTI FT data were available for resection planning and intraoperative guidance. Clinical outcome parameters, including craniotomy size, extent of resection (EOR), language deficits at different time points, Karnofsky Performance Scale (KPS) score, duration of surgery, and inpatient stay, were assessed. According to postoperative evaluation, 28.3% of patients showed tumor residuals, whereas new surgery-related permanent language deficits occurred in 8.3% of patients. KPS scores remained unchanged. According to the authors, this is the first study to present a clinical outcome analysis of this modern approach, which is increasingly applied in neuro-oncological centers worldwide. The authors indicated that although human language function is a highly complex and dynamic cortico-subcortical network, the presented approach offers excellent functional and oncological outcomes in patients undergoing surgery of lesions affecting this network. According the authors, a limitation of this study is that it analyzed clinical outcome without a control group; thus, follow-up studies that include randomized controlled trials are needed to prove the optimized outcome in comparison to patients who do not undergo such an extensive preoperative workup.

# U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

On December 13, 2013, the Cerena™ Transcranial Magnetic Stimulator (TMS) (eNeura Therapeutics®) received FDA approval thru the de novo premarket review pathway, a regulatory pathway for low- to moderate-risk medical devices that are not substantially equivalent to an already legally marketed device. According to the FDA documents, the Cerena Transcranial Magnetic Stimulator is indicated for the acute treatment of pain associated with migraine headache with aura. See the following websites for more information:

- [http://www.accessdata.fda.gov/cdrh\\_docs/pdf13/K130556.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf13/K130556.pdf)
- [http://www.accessdata.fda.gov/cdrh\\_docs/reviews/K130556.pdf](http://www.accessdata.fda.gov/cdrh_docs/reviews/K130556.pdf)

(Accessed February 25, 2021)

The SpringTMS (eNeura Therapeutics) has received multiple FDA 510(k) clearances. The initial clearance on May 21, 2014 was predicated on the Cerena device by the same manufacturer. Subsequent clearances were granted for modifications in the size and design of the device with no changes to the basic technology. See the following website for more information:

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmnmn.cfm?ID=K140094>. (Accessed February 25, 2021)

For a complete list of cleared products for transcranial magnetic stimulator for headache, see the following websites (use product code OKP):

- <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmnmn.cfm>
- <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm>

(Accessed February 25, 2021)

In 2009, the FDA cleared the eXimia Navigated Brain Stimulation System (NBS) System (Nexstim) for use in pre-surgical planning for patients undergoing brain surgery. The NBS uses transcranial magnetic stimulation (TMS) guided by standard MR-image data, a non-invasive direct technique for functional mapping of the motor cortex. See the following website for more information: [http://www.accessdata.fda.gov/cdrh\\_docs/pdf9/K091457.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf9/K091457.pdf). (Accessed February 25, 2020)

The Navigated Brain Stimulation (NBS) System (Nexstim) received 510(k) clearance on May 22, 2012. See the following website for more information: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf11/K112881.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf11/K112881.pdf). (Accessed February 25, 2021)

## Additional Products

Neuralie TMS device

## References

- Chen R, Spencer DC, Weston J, et al. Transcranial magnetic stimulation for the treatment of epilepsy. Cochrane Database Syst Rev. 2016 Aug 11;(8):CD011025.
- Cotoi A, Mirkowski M, Iruthayarajah J, et al. The effect of theta-burst stimulation on unilateral spatial neglect following stroke: a systematic review. Clin Rehabil. 2019 Feb;33(2):183-194.
- Cruccu G, Garcia-Larrea L, Hansson P, et al. EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol. 2016 Oct;23(10):1489-99.
- Dionísio A, Duarte IC, Patrício M, et al. The use of repetitive transcranial magnetic stimulation for stroke rehabilitation: a systematic review. J Stroke Cerebrovasc Dis. 2017 Oct 27. pii: S1052-3057(17)30479-2.
- Dong X, Yan L, Huang L, et al. Repetitive transcranial magnetic stimulation for the treatment of Alzheimer's disease: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2018 Oct 12;13(10):e0205704.
- Frey D, Schilt S, Strack V, et al. Navigated transcranial magnetic stimulation improves the treatment outcome in patients with brain tumors in motor eloquent locations. Neuro Oncol. 2014 Oct;16(10):1365-72.
- Galhardoni R, Aparecida da Silva V, García-Larrea L, et al. Insular and anterior cingulate cortex deep stimulation for central neuropathic pain: Disassembling the percept of pain. Neurology. 2019 Apr 30;92(18):e2165-e2175.

Gatzinsky K, Bergh C, et al. (2020). Repetitive transcranial magnetic stimulation of the primary motor cortex in management of chronic neuropathic pain: a systematic review. *Scand J Pain*. 2020 Sep 7;21(1):8-21

Ghayour-Najafabadi M, Memari AH, Hosseini L, et al. Repetitive transcranial magnetic stimulation for the treatment of lower limb dysfunction in patients poststroke: a systematic review with meta-analysis. *J Stroke CerebrovascDis*. 2019 Dec;28(12):104412.

Goodwill AM, Lum JAG, Hendy AM, et al. Using non-invasive transcranial stimulation to improve motor and cognitive function in Parkinson's disease: a systematic review and meta-analysis. *Sci Rep*. 2017 Nov 1;7(1):14840.

Goudra B, Shah D, Balu G, et al. Repetitive transcranial magnetic stimulation in chronic pain: A Meta-analysis. *Anesth Essays Res*. 2017 Jul-Sep;11(3):751-757.

Hamid P, Malik BH, Hussain ML. Noninvasive transcranial magnetic stimulation (TMS) in chronic refractory pain: a systematic review. *Cureus*. 2019 Oct29;11(10):e6019.

Hayes Inc. Hayes Brief. The clinical utility of navigated transcranial magnetic stimulation for presurgical planning for brain tumors. Lansdale, PA: Hayes. May 18, 2017. Updated May 2019.

Hayes Inc. Hayes Emerging Technology Report. NeuroAD Therapy System for Alzheimer Disease. Lansdale, PA: Hayes. April 2019.

Hayes Inc. Search and Summary. Single-pulse transcranial magnetic stimulation using SpringTMS (eNeura Inc.) for treatment of acute migraines. Lansdale, PA: Hayes. February 2018. Archived March 2019.

Holczer A, Németh VL, Vékony T, et al., Non-invasive brain stimulation in Alzheimer's disease and mild cognitive impairment-a state-of-the-art review on methodological characteristics and stimulation parameters. *Front Hum Neurosci*. 2020 May 25;14:179.

Klomjai W, Katz R, Lackmy-Vallée A. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). *Ann Phys Rehabil Med*. 2015 Sep;58(4):208-13.

Liang Z, Yang H, Cheng G, Huang L, Zhang T, Jia H. Repetitive transcranial magnetic stimulation on chronic tinnitus: a systematic review and meta-analysis. *BMC Psychiatry*. 2020 Nov 23;20(1):547.

Lin Y, Jiang WJ, Shan PY, et al. The role of repetitive transcranial magnetic stimulation (rTMS) in the treatment of cognitive impairment in patients with Alzheimer's disease: A systematic review and meta-analysis. *J Neurol Sci*. 2019 Mar 15;398:184-191.

Martelletti P, Jensen RH, Antal A, et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. *J Headache Pain*. 2013 Oct 21;14(1):86.

McIntyre A, Mirkowski M, Thompson S, et al. A systematic review and meta-analysis on the use of repetitive transcranial magnetic stimulation for spasticity post stroke. *PM R*. 2017 Oct 15. pii: S1934-1482(17)31359-X.

Moisset X, Pereira B, Ciampi de Andrade D, et al. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. *J Headache Pain*. 2020 Dec 10;21(1):142

National Institute for Health and Care Excellence (NICE). 2018. Guideline for dementia: assessment, management and support for people living with dementia and their careers.

National Institute for Health and Care Excellence (NICE). (2014) Transcranial magnetic stimulation for treating and preventing migraine.

O'Connell NE, Marston L, Spencer S, et al. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev*. 2018 Apr 13;4:CD008208.

Pichora-Fuller MK, Santaguida P, Hammill A, et al. Evaluation and Treatment of Tinnitus: Comparative Effectiveness. Comparative Effectiveness Review No. 122. (Prepared by the McMaster University Evidence-based Practice Center under Contract No. 290-2007-10060- I.) AHRQ Publication No. 13-EHC110-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2013.

Pringsheim T, Holler-Managan Y, Okun MS, et al. Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. *Neurology*. 2019 May 7;92(19):907-915.

Rabey JM, Dobronevsky E, Aichenbaum S, et al. Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: a randomized, double-blind study. *J Neural Transm*. 2013 May;120(5):813-9.

Raffa G, Scibilia A, Conti A, et al., The role of navigated transcranial magnetic stimulation for surgery of motor-eloquent brain tumors: a systematic review and meta-analysis. *Clin Neurol Neurosurg.* 2019 May;180:7-17.

Raffa G, Quattropiani MC, Scibilia A, et al. Surgery of language-eloquent tumors in patients not eligible for awake surgery: the impact of a protocol based on navigated transcranial magnetic stimulation on presurgical planning and language outcome, with evidence of tumor-induced intra-hemispheric plasticity. *Clin Neurol Neurosurg.* 2018 May;168:127-139.

Reuter U, McClure C, Liebler E, et al. Non-invasive neuromodulation for migraine and cluster headache: a systematic review of clinical trials. *J Neurol Neurosurg Psychiatry.* 2019 Jul;90(7):796-804.

Saltychev M, Laimi K. Effectiveness of repetitive transcranial magnetic stimulation in patients with fibromyalgia: a meta-analysis. *Int J Rehabil Res.* 2017 Mar;40(1):11-18.

Sebastianelli L, Versace V, Martignago S, et al. Low-frequency rTMS of the unaffected hemisphere in stroke patients: A systematic review. *Acta Neurol Scand.* 2017 Dec;136(6):585-605.

Shirahige L, Melo L, Nogueira F, et al. Efficacy of noninvasive brain stimulation on pain control in migraine patients: a systematic review and meta-analysis. *Headache.* 2016 Nov;56(10):1565-1596.

Soleimani R, Jalali MM, Hasandokht T. Therapeutic impact of repetitive transcranial magnetic stimulation (rTMS) on tinnitus: a systematic review and meta-analysis. *Eur Arch Otorhinolaryngol.* 2016 Jul;273(7):1663-75.

Sollmann N, Kelm A, Ille S, et al. Setup presentation and clinical outcome analysis of highly treating language-eloquent gliomas via preoperative navigated transcranial magnetic stimulation and tractography. *Neurosurg Focus.* 2018 Jun;44(6):E2.

Stilling JM, Monchi O, Amoozegar F, et al. Transcranial magnetic and direct current stimulation (TMS/tDCS) for the treatment of headache: a systematic review. *Headache.* 2019 Mar;59(3):339-357.

Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: tinnitus. *Otolaryngol Head Neck Surg.* 2014 Oct;151(2 Suppl):S1-40.

Wagle Shukla A, Shuster JJ, Chung JW, et al. Repetitive Transcranial Magnetic Stimulation (rTMS) Therapy in Parkinson Disease: A Meta-Analysis. *PM R.* 2016 Apr;8(4):356-66.

Winkelman, JW, Armstrong, MJ, Allen, RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 2016;87(24):2585-93. Reaffirmed on October 12, 2019.

Xie YJ, Gao Q, He CQ, et al. Effect of repetitive transcranial magnetic stimulation on gait and freezing of gait in Parkinson's disease: a systematic review and meta-analysis. *Arch Phys Med Rehabil.* 2020 Jan;101(1):130-140.

Xie YJ, Chen Y, Tan HX, Guo QF, Lau BW, Gao Q. Repetitive transcranial magnetic stimulation for lower extremity motor function in patients with stroke: a systematic review and network meta-analysis. *Neural Regen Res.* 2021 Jun;16(6):1168-1176.

Yang C, Guo Z, Peng H, et al. Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Meta-analysis. *Brain Behav.* 2018 Sep 28:e01132.

Yu B, Qiu H, Li J, et al. Noninvasive brain stimulation does not improve neuropathic pain in individuals with spinal cord injury: evidence from a meta-analysis of 11 randomized controlled trials. *Am J Phys Med Rehabil.* 2020 Sep;99(9):811-820.

## Policy History/Revision Information

Date	Summary of Changes
02/01/2023	<ul style="list-style-type: none"> <li>Created state-specific policy version</li> </ul>
05/01/2021	<p><b>Template Update</b></p> <ul style="list-style-type: none"> <li>Replaced content sub-heading titled “Professional Societies” with “Clinical Practice Guidelines” in <i>Clinical Evidence</i> section</li> </ul>
04/01/2021	<p><b>Supporting Information</b></p> <ul style="list-style-type: none"> <li>Removed <i>CMS</i> section</li> <li>Updated <i>Clinical Evidence</i> and <i>References</i> sections to reflect the most current information</li> <li>Archived previous policy version CS124.H</li> </ul>

## Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual<sup>®</sup> criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.